Increased serum Neurofilament light chain levels in Parkinson's Disease patients carrying the p.A53T SNCA mutation: Data from the PPMI study

IntroductionSerum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinsons Disease (iPD) have been inconsistent. The p.A53T mutation in the SNCA gene usually leads to a severe, rapidly progressing genetic form of PD. ObjectivesAssessing the possible use of serum NfL as a marker of ongoind neurodegeneration in A53T-PD. MethodsUsing a propensity score matching based technique with data from the Parkinsons Progression Markers Initiative, A53T-PD participants were matched, in a 3:1 ratio, to iPD patients and healthy controls by age and disease duration, where applicable. ResultsAfter matching, 18 A53T-PD, 54 iPD, and 54 controls were analyzed. Serum NfL was significantly higher in A53T-PD (9.82 [8.02-18.1] pg/ml) compared to HC (7.54 [5.76-10.1]) or iPD (8.59 [6.86-11.1]) [overall p=0.049]. ConclusionThe increase in serum NfL points to a more aggressive neurodegenerative process in A53T-PD compared to iPD. This finding may help design and implement Disease-modifying treatments (DMTs) in this select group of prototypical genetic PD.